India is taking significant steps to enhance its vaccination strategy, with a special focus on adults, particularly those aged 55 and above, said Dr. N K Arora, Member of the National Technical Advisory Group on Immunisation in India (NTAGI), as part of the World Immunization Week. NTAGI is the highest advisory body on immunization in the country, which consists of independent experts who provide recommendations on vaccines after reviewing data on disease burden, efficacy, and cost-effectiveness of vaccines. In an exclusive interaction with HealthandMe, Dr. Arora shared that the country “is in the process of establishing priority pathogens and vaccines aimed at the adult population”. This initiative will target those above the age of 55 or 60 to tackle infections that are particularly serious in older individuals, especially those living with chronic conditions like diabetes, hypertension, and cancer. “The process has started. This year, we will be moving in that direction,” said Dr. Arora.HPV Vaccination: A Milestone in Preventing Cervical Cancer The expert lauded the introduction of the HPV vaccine for young girls. Dr. Arora highlighted the critical importance of this initiative, given India’s status as the country with the highest number of cervical cancer cases globally. "Cervical cancer is preventable by the HPV vaccine, and we are now in the fortunate position of having a domestically manufactured vaccine," he explained. The first round of vaccinations has already commenced, and Dr. Arora urged the media and public to dispel any misinformation surrounding the vaccine to ensure its success. An Indigenous Dengue Vaccine Further, the vaccine expert highlighted the potential introduction of an indigenous dengue vaccine, currently undergoing trials. “The trials will take at least two and a half years, which means by the end of 28, we will have the results,” Dr. Arora said. He emphasized the severity of dengue when it turns from a mild illness into a severe one, particularly among young adults. The dengue vaccine, being developed indigenously, is expected to play a crucial role in protecting the 10-20 age group, who are most susceptible to severe dengue cases. “We are waiting for the results of the trials, and once the vaccine is recommended by the NTAGI, the system will be ready to adopt it,” said Dr. Arora. Also read: World Immunization Week: Vaccines Are Like Insurance, They’re Safe—Take Them, Says Dr NK Arora | ExclusiveIndia In The Forefront of Vaccine R&D Dr. Arora stated that India, known as the pharmacy of the world, is playing a significant role in the global vaccine landscape. “One feels very proud to be an Indian as every vaccine administered in India is made in India,” he said, noting that India also "provides two-thirds of the global vaccine supply". This achievement positions India as a global leader in vaccine research and development, contributing substantially to global health initiatives. "These initiatives are vital for the future of public health in India," Dr. Arora said.